

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1-57. (Cancelled)

58. (Currently Amended) An assay device for identifying a leukemia of T-cell, B-cell, or myeloid lineage in a subject, said device comprising (a) a solid support; and (b) an array of immunoglobulin molecules, or derivatives thereof, immobilized to discrete regions on the solid support, wherein the array comprises from 7 to about 1000 discrete regions, wherein each discrete region comprises an immunoglobulin, or derivative thereof, specific for a cell surface marker antigen such that the array comprises immunoglobulins specific for 7 to about 1000 cell surface marker antigens, wherein the array comprises immunoglobulin molecules specific for ~~at least seven~~ cell surface marker antigens selected from the list in Table 4, and wherein the pattern of expression of the 7 to about 1000 cell surface marker antigens on a leukocyte distinguishes leukemias of T-cell, B-cell, or myeloid lineage.

59-68. (Cancelled)

69. (Previously Presented) The assay device of claim 58 wherein the subject is a human.

70. (Cancelled)

71. (Previously Presented) The assay device of claim 58, wherein the immunoglobulins, or derivatives thereof, of the array are bound covalently to the solid support or wherein the immunoglobulins, or derivatives thereof, of the array are bound to a recombinant, truncated protein G that is first coated on the solid support.

72. (Previously Presented) The method of claim 58 wherein the subject is a non-human animal.

73. (Previously Presented) The method of Claim 58, wherein the immunoglobulin molecules are monoclonal antibodies.

74. (Previously Presented) The method of Claim 58, wherein the immunoglobulin molecules are polyclonal antibodies.